ESMO Asia 2016: First-in-class inhibitor of FGFR2 shows promising results in preclinical studies

ESMO Asia 2016: First-in-class inhibitor of FGFR2 shows promising results in preclinical studies/news/b/pressreleases/archive/2016/12/21/esmo-asia-2016-firstinclass-inhibitor-of-fgfr2-shows-promising-results-in-preclinical-studies.aspxSINGAPORE – A novel allosteric fibroblast growth factor receptor 2 (FGFR2) inhibitor, alofanib, has potent anti-tumour and antiangiogenic activity, according to the results of preclinical studies. The results were presented at the ESMO Asia 20167.x Production